Volume 9 Issue 5
Sep.  2018
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2018  >  9(5): 379-384
Sun Kai, Liu Yongbao. CRRT combined with immunoabsorption and plasma exchange in treatment of AMR complicated with multiple organ failure after renal transplantation[J]. ORGAN TRANSPLANTATION, 2018, 9(5): 379-384. doi: 10.3969/j.issn.1674-7445.2018.05.010
Citation: Sun Kai, Liu Yongbao. CRRT combined with immunoabsorption and plasma exchange in treatment of AMR complicated with multiple organ failure after renal transplantation[J]. ORGAN TRANSPLANTATION, 2018, 9(5): 379-384. doi: 10.3969/j.issn.1674-7445.2018.05.010
shu

CRRT combined with immunoabsorption and plasma exchange in treatment of AMR complicated with multiple organ failure after renal transplantation

doi: 10.3969/j.issn.1674-7445.2018.05.010

  • The 309th Hospital of People's Liberation Army, Beijing 100091, China

More Information
  • Corresponding author: Sun Kai, Email:18612496040@163.com
  • Received Date: 2017-07-12
    Available Online: 2021-01-19
  • Publish Date: 2018-09-15
    Abstract
  •   Objective  To investigate the clinical efficacy of continuous renal replacement therapy (CRRT) combined with immunoabsorption and plasma exchange in the treatment of antibody-mediated rejection (AMR) complicated with multiple organ failure after renal transplantation.  Methods  Twenty-eight patients diagnosed with AMR complicated with multiple organ failure after renal transplantation were randomly divided into the control group (n=12) and treatment group (n=16).All patients were given with methylprednisolone 0.8 g/d shock therapy for 5 d, oral intake of ciclosporin 1.5 mg/(kg·d), CRRT, cardiotonics, diuretics and other symptomatic treatments.In the treatment group, immunoabsorption and plasma exchange were delivered on the 7th and 10th d after treatment.The overall conditions were statistically compared between two groups.The changes of renal function [blood urea nitrogen (BUN), serum creatinine (Scr)] and blood electrolyte before and after treatment were compared between two groups.The results of histopathological examination and immunohistochemical staining of the renal tissues before and after treatment were analyzed in two groups.  Results  Among 28 patients, 24 cases were clinically cured, including 14 in the treatment group and 10 in the control group.The symptoms of 3 patients were deteriorated, including 2 in the treatment group and 1 in the control group.One patient in the control group died of cerebral hemorrhage.After 7 d and 12 d treatment, the levels of BUN and Scr significantly differed between the treatment group and control group (P < 0.05-0.01).The levels of blood sodium and potassium significantly differed between two groups before and after treatment (P < 0.05-0.01).Pathological examination of renal tissue demonstrated that after 12 d treatment, the number of lymphocytes infiltrated in the transplanted kidney tissues was reduced and the degree of vasculitis was alleviated in two groups.Compared with the control group, the pathological scores of glomerulus, tubulointerstitial and blood vessels were significantly lower in the treatment group (all P < 0.01).Immunohistochemical staining revealed that after 12 d treatment, the number of ED1-positive monocytes in the transplanted kidney tissues was declined in both groups, especially in the treatment group.Following 12 d treatment, the ratio of CD4+/CD8+ cells in renal tubulointerstitial in the treatment group was significantly lower than that in the control group (P < 0.01).  Conclusions   CRRT combined with immunoabsorption and plasma exchange is an effective method to treat AMR complicated with multiple organ failure following renal transplantation.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    LEE JM, LEE SA, CHO HJ, et al.Impact of perioperative renal dysfunction in heart transplantation:combined heart and kidney transplantation could help to reduce postoperative mortality[J].Ann Transplant, 2013, 18:533-549.DOI: 10.12659/AOT.889103.
    [2]
    XU C, CARLSSON DO, MIHRANYAN A.Feasibility of using DNA-immobilized nanocellulose-based immunoadsorbent for systemic lupus erythematosus plasmapheresis[J].Colloids Surf B Biointerfaces, 2016, 143:1-6.DOI: 10.1016/j.colsurfb.2016.03.014.
    [3]
    HAAS M, LOUPY A, LEFAUCHEUR C, et al.The Banff 2017 Kidney Meeting Report:revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials[J].Am J Transplant, 2018, 18(2):293-307.DOI: 10.1111/ajt.14625.
    [4]
    AUBERT O, LOUPY A, HIDALGO L, et al.Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients[J].J Am Soc Nephrol, 2017, 28(6):1912-1923.DOI: 10.1681/ASN.2016070797.
    [5]
    SKRIAPA L, ZISIMOPOULOU P, TRAKAS N, et al.Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy[J].J Neuroimmunol, 2014, 276(1/2):150-158.DOI: 10.1016/j.jneuroim.2014.09.013.
    [6]
    KIM J, CHOI SE, LIM BJ, et al.Clinical significance of macrophage polarization in antibody-mediated rejection of renal allograft[J].Transplant Proc, 2018, 50(4):1005-1008.DOI: 10.1016/j.transproceed.2018.02.037.
    [7]
    EINECKE G, BRÄSEN JH, HANKE N, et al.Fatal pneumococcus sepsis after treatment of late antibody-mediated kidney graft rejection[J].Case Rep Nephrol, 2018:1415450.DOI: 10.1155/2018/1415450.
    [8]
    LAN JH, GJERTSON D, ZHENG Y, et al.Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction[J].Am J Transplant, 2018, DOI:10.1111/ajt.14871[Epubahead of print].
    [9]
    REDONDO-PACHÓN D, PÉREZ-SÁEZ MJ, MIR M, et al.Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes[J].Hum Immunol, 2018, 79(6):424-431.DOI: 10.1016/j.humimm.2018.02.014.
    [10]
    MONTGOMERY RA, LOUPY A, SEGEV DL.Antibody-mediated rejection:new approaches in prevention and management[J].Am J Transplant, 2018, 18(Suppl 3):3-17.DOI: 10.1111/ajt.14584.
    [11]
    罗子寰, 孙启全.肾移植基础研究2016年盘点[J].器官移植, 2017, 8(1):15-21.DOI:10.3969/j.issn.1674- 7445.2017.01.004.

    LUO ZH, SUN QQ.Summary of basic study on renal transplantation in 2016[J].Organ Transplant, 2017, 8(1):15-21.DOI: 10.3969/j.issn.1674-7445.2017.01.004.
    [12]
    BAILLY E, ANGLICHEAU D, BLANCHO G, et al.Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation[J].Transplantation, 2018, 102(4):688-698.DOI: 10.1097/TP.0000000000002002.
    [13]
    MORESO F, CRESPO M, RUIZ JC, et al.Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab:a multicenter, prospective, randomized, double-blind clinical trial[J].Am J Transplant, 2018, 18(4):927-935.DOI: 10.1111/ajt.14520.
    [14]
    GARG N, SAMANIEGO MD, CLARK D, et al.Defining the phenotype of antibody-mediated rejection in kidney transplantation:advances in diagnosis of antibody injury[J].Transplant Rev (Orlando), 2017, 31(4):257-267.DOI: 10.1016/j.trre.2017.08.005.
    [15]
    SOUTH AM, MAESTRETTI L, KAMBHAM N, et al.Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients[J].Pediatr Transplant, 2017, 21(7).DOI: 10.1111/petr.13035.
    [16]
    MATIGNON M, PILON C, COMMEREUC M, et al.Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA:results of an observational study[J].PLoS One, 2017, 12(6):e0178572.DOI: 10.1371/journal.pone.0178572.
    [17]
    PARKES MD, HALLORAN PF, HIDALGO LG.Mechanistic sharing between NK cells in ABMR and effector T cells in TCMR[J].Am J Transplant, 2018, 18(1):63-73.DOI: 10.1111/ajt.14410.
    [18]
    LACHMANN N, DUERR M, SCHÖNEMANN C, et al.Treatment of antibody-mediated renal allograft rejection:improving step by step[J].J Immunol Res, 2017:6872046.DOI: 10.1155/2017/6872046.
    [19]
    WU GS, CRUZ RJ JR, CAI JC.Acute antibody-mediated rejection after intestinal transplantation[J].World J Transplant, 2016, 6(4):719-728.DOI: 10.5500/wjt.v6.i4.719.
    [20]
    HIRANO R, HIRATA N.Immunoadsorption using immusorba TR and PH[J].Transfus Apher Sci, 2017, 56(5):661-665.DOI: 10.1016/j.transci.2017.08.011.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (149) PDF downloads(7) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return